Tandem Diabetes Care, Inc. (TNDM)

Market Cap	1.28B
Revenue (ttm)	940.20M
Net Income (ttm)	-96.03M
Shares Out	66.47M
EPS (ttm)	-1.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	856,610
Open	19.71
Previous Close	19.81
Day's Range	18.87 - 19.72
52-Week Range	17.64 - 53.69
Beta	1.45
Analysts	Buy
Price Target	46.07 (+138.95%)
Earnings Date	May 1, 2025

About TNDM

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company’s flagship product is the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user’s body. In addition, the company offers Tandem Device Updater used to update the pump software fr...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Nov 14, 2013
• Employees: 2,650
• Stock Exchange: NASDAQ
• Ticker Symbol: TNDM
• Website: https://www.tandemdiabetes.com

Financial Performance

In 2024, Tandem Diabetes Care's revenue was $940.20 million, an increase of 25.74% compared to the previous year's $747.72 million. Losses were -$96.03 million, -56.86% less than in 2023.

Analyst Forecast

According to 15 analysts, the average rating for TNDM stock is "Buy." The 12-month stock price forecast is $46.07, which is an increase of 138.95% from the latest price.

Price Target

$46.07

(138.95% upside)

Analyst Consensus: Buy